{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:19:48Z","timestamp":1761664788377,"version":"3.40.5"},"reference-count":38,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:00:00Z","timestamp":1726617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ekir.2024.09.016","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T13:15:50Z","timestamp":1727097350000},"page":"3446-3454","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy"],"prefix":"10.1016","volume":"9","author":[{"given":"Hongyu","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjun","family":"Luan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinglei","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beiru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9052-186X","authenticated-orcid":false,"given":"Jeffrey B.","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2024.09.016_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.ajkd.2010.01.008","article-title":"The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey","volume":"56","author":"Glassock","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.09.016_bib2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.016_bib4","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","article-title":"KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases","volume":"100","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.016_bib5","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ekir.2024.05.028","article-title":"Key points in managing PLA2R-associated membranous nephropathy","volume":"9","author":"Ramachandran","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.016_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.016_bib7","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib8","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1681\/ASN.2013020185","article-title":"Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy","volume":"25","author":"van den Brand","year":"2014","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2024.09.016_bib10","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1080\/17512433.2016.1225497","article-title":"Pharmacological treatment of primary membranous nephropathy in 2016","volume":"9","author":"van de Logt","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.ekir.2024.09.016_bib11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.autrev.2016.12.005","article-title":"Calcineurin inhibitors versus cyclophosphamide for idiopathic membranous nephropathy: a systematic review and meta-analysis of 21 clinical trials","volume":"16","author":"Qiu","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2024.09.016_bib12","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012476","article-title":"Hydroxychloroquine in rheumatic autoimmune disorders and beyond","volume":"12","author":"Nirk","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ekir.2024.09.016_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.016_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","article-title":"Update on lupus nephritis: core curriculum 2020","volume":"76","author":"Parikh","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.09.016_bib15","article-title":"Hydroxychloroquine inhibits macrophage activation and attenuates renal fibrosis after ischemia-reperfusion injury","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2024.09.016_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/j.ajkd.2019.01.026","article-title":"Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial","volume":"74","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2024.09.016_bib17","first-page":"1145","article-title":"Effects of hydroxychloroquine on proteinuria in membranous nephropathy","volume":"35","author":"Cheng","year":"2022","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1681\/ASN.2015111262","article-title":"Membranous nephropathy: quantifying remission duration on outcome","volume":"28","author":"Cattran","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib19","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1681\/ASN.2015010091","article-title":"Complete and partial remission as surrogate end points in membranous nephropathy","volume":"26","author":"Thompson","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.2215\/CJN.01330209","article-title":"The natural history of the non-nephrotic membranous nephropathy patient","volume":"4","author":"Hladunewich","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2024.09.016_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2024.09.016_bib23","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.ekir.2024.09.016_bib25","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"2019 update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2024.09.016_bib26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12882-019-1488-6","article-title":"Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study","volume":"20","author":"Yang","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib27","article-title":"The effect of hydroxychloroquine on residual proteinuria in patients with immunoglobulin A nephropathy: a retrospective study based on propensity score matching","volume":"9","author":"Liu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2024.09.016_bib28","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.2174\/1381612826666200707132920","article-title":"The role of chloroquine and hydroxychloroquine in immune regulation and diseases","volume":"26","author":"Martinez","year":"2020","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ekir.2024.09.016_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.79.1.175","article-title":"Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells","volume":"79","author":"Ziegler","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2024.09.016_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/icb.2013.73","article-title":"Dendritic cells treated with chloroquine modulate experimental autoimmune encephalomyelitis","volume":"92","author":"Thom\u00e9","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.ekir.2024.09.016_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0287738","article-title":"Hydroxychloroquine reduces T cells activation recall antigen responses","volume":"18","author":"Kowatsch","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2024.09.016_bib32","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2337\/dc23-1096","article-title":"Hydroxychloroquine in Stage 1 type 1 diabetes","volume":"46","author":"Libman","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ekir.2024.09.016_bib33","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaad.2017.01.012","article-title":"Updated recommendations on the use of hydroxychloroquine in dermatologic practice","volume":"76","author":"Fernandez","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.ekir.2024.09.016_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101812","article-title":"Hydroxychloroquine safety: a meta-analysis of randomized controlled trials","volume":"36","author":"Eljaaly","year":"2020","journal-title":"Travel Med Infect Dis"},{"key":"10.1016\/j.ekir.2024.09.016_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ekir.2024.09.016_bib36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/BOR.0000000000000872","article-title":"Advances in the clinical use of hydroxychloroquine levels","volume":"34","author":"Chakrabarti","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ekir.2024.09.016_bib37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1681\/ASN.2016070776","article-title":"A\u00a0proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2024.09.016_bib38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.2215\/CJN.0000000000000237","article-title":"Anti-PLA2R antibody levels and clinical risk factors for treatment nonresponse in membranous nephropathy","volume":"18","author":"Barbour","year":"2023","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024924019442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T09:09:08Z","timestamp":1733216948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024924019442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2468024924019442"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.016","relation":{},"ISSN":["2468-0249"],"issn-type":[{"type":"print","value":"2468-0249"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Trial of Hydroxychloroquine as Add-On Therapy in Patients With Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2024.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}